Quantcast
Last updated on April 19, 2014 at 1:20 EDT

Latest Autoantibody Stories

2013-06-19 12:27:08

--Long-term study reveals that multiple islet autoantibodies in young children indicate a high risk of developing type 1 diabetes within 10 years, clarifying the window for potential prevention strategies-- NEW YORK, June 19, 2013 /PRNewswire-USNewswire/ -- A decade-long JDRF-funded study led by the Institute of Diabetes Research in Helmholtz Zentrum München, Germany, is providing a deeper understanding of the link between autoantibodies and the risk of developing type 1...

2013-06-03 08:26:58

Awards Will Support Efforts of Tomorrow's Lupus Thought Leaders to Solve the Cruel Mystery of this Unpredictable and Devastating Disease WASHINGTON, June 3, 2013 /PRNewswire-USNewswire/ -- The Lupus Foundation of America, the only national force dedicated to solving the cruel mystery of lupus, announced recipients of five new summer fellowships and the Foundation's first-ever Career Development Award. The Foundation presents these awards to foster interest in a career in lupus...

2013-04-30 04:21:04

Innovative and high quality product lines set new benchmarks for the autoimmune disease diagnostics market LONDON, April 30, 2013 /PRNewswire/ -- Based on its recent analysis of the autoimmune disease diagnostics market, Frost & Sullivan recognises Euro Diagnostica AB with the 2013 Europe Product Differentiation Excellence Award. "Euro Diagnostica offers a range of high-quality enzyme linked immunosorbent assay (ELISA) kits for autoimmune diagnostics," noted Frost &...

2013-04-24 08:28:56

BREDA, The Netherlands and GHENT, Belgium, April 24, 2013 /PRNewswire/ -- First program based on proprietary ABDEG(TM) technology to promote degradation and clearance of disease-causing autoantibodies arGEN-X, a clinical stage biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announces that it has progressed its second product candidate this year into formal preclinical development. Complementing its...

2013-03-27 16:27:43

HAYWARD, Calif., March 27, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced it has initiated the CHABLIS-SC1 Phase 3 study of blisibimod, a novel inhibitor of B-Cell Activating Factor (BAFF) for the treatment of systemic lupus erythematosus (lupus). Lupus is a chronic autoimmune disease, which often leads to severe skin rash, fatigue,...

2013-02-27 20:23:46

Partners to Develop Novel Nuclease Proteins for Lupus OSAKA, Japan and SEATTLE, Feb. 27, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and Resolve Therapeutics, LLC ("Resolve") today jointly announced that they have entered into a partnership to develop compounds for the treatment of lupus (also known as Systemic Lupus Erythematosus, or SLE) and other autoimmune diseases. The lead compound, RSLV-132, a novel nuclease(*1) Fc fusion protein(*2), will begin...

2013-01-31 12:28:53

NEW YORK, Jan. 31, 2013 /PRNewswire/ -- The Lupus Research Institute (LRI) - world's leading supporter of innovative research in lupus -- today awards $3.6 million in Novel Research Grants to allow 12 investigators to pursue ground-breaking studies with potential for transformative results. The $300,000 grants provide scientists with the resources to devote their talent to lupus research for three years. In just its first decade of service, the LRI has awarded more than $40 million for novel...

2013-01-29 08:30:18

LEIDEN, The Netherlands and SAN DIEGO, Jan. 29, 2013 /PRNewswire/ -- Leiden University Medical Center (LUMC) and INOVA Diagnostics are pleased to announce the completion of an exclusive, worldwide license agreement for technology developed at LUMC to detect antibodies to carbamylated proteins (anti-CarP). This technology represents an important advance in the diagnosis of Rheumatoid Arthritis (RA). "The detection of autoantibodies in sera of RA patients has provided important insight into...

2013-01-22 08:30:36

SAN DIEGO, Jan. 22, 2013 /PRNewswire/ -- INOVA Diagnostics is pleased to announce the full commercial launch of BIO-FLASH, a rapid-response chemiluminescent analyzer for use by clinical reference and hospital laboratories. This signals the global release of BIO-FLASH along with QUANTA Flash® reagents for autoimmune disease diagnostic testing. BIO-FLASH is a technologically advanced analyzer which offers full automation of a broad menu of highly accurate QUANTA Flash immunoassays for...

2013-01-08 00:20:36

GLEN ALLEN, Va., Jan. 7, 2013 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: STSI) announced today the preliminary results of the Company's ASAP (Anatabloc Supplementation Autoimmune Prevention) Human Thyroid Study that analyzes the impact of anatabine dietary supplementation on thyroid health. (Logo: http://photos.prnewswire.com/prnh/20120301/NE62741LOGO ) The study is a three-month, five-visit, double-blind, placebo-controlled study of the impact of anatabine dietary supplementation in...